Journal of Molecular Cell Biology Advance Access originally published online on August 14, 2009
Journal of Molecular Cell Biology 2009 1(1):17-19; doi:10.1093/jmcb/mjp011
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CCR3: Shedding New Light on a Dark Problem?
Yale School of Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06510, USA
* Correspondence to: A. Brett Mason, E-mail: alan.mason{at}yale.edu; Josephine Hoh, E-mail: josephine.hoh{at}yale.edu
| Abstract |
|---|
A recent work by Ambati et al. represents a bold step towards a more effective diagnosis and treatment of age-related macular degeneration, with the new evidence showing that CCR3, a chemokine receptor, is an early marker of and potential therapeutic target for choroidal neovascularization development. In the wake of such a novel and significant finding, additional illumination to confirm and consolidate the promise shown by CCR3 will soon follow.
Received July 13, 2009; Accepted July 13, 2009